PT-141, or bremelanotide, is a cyclic heptapeptide melanocortin-receptor agonist derived from the earlier melanotan-II scaffold, with a modification that replaces the terminal amide and closes a ring. Its structure is a study in how a small change to a related peptide can shift its receptor character.
Cyclic melanocortin core
A lactam bridge locks the peptide into a constrained ring, favoring the folded conformation that engages melanocortin receptors — the structural basis of its mechanism of action. Cyclization reduces the number of flexible conformations the chain can adopt, which can sharpen receptor selectivity.
Relationship to melanotan-II
PT-141 shares the core motif of melanotan-II but replaces the C-terminal amide with a carboxylic acid, a change that shifts its receptor selectivity. In effect, it corresponds to a deaminated derivative of the melanotan-II scaffold, which is why the two are so often compared.
Why the ring matters
Constraining a peptide into a ring is a common medicinal-chemistry strategy for improving stability and defining a single preferred shape. For a melanocortin-family peptide, that defined shape is closely tied to which receptor subtypes it engages most strongly.
Synthesis and cyclization
PT-141 is made by solid-phase peptide synthesis with on-resin cyclization to form the lactam bridge, then cleaved, purified, and lyophilized (what is lyophilization) to a dry research powder.
Identity verification
Correct ring closure and sequence are confirmed by HPLC and mass spectrometry. Historical context is in PT-141 discovery and history.
Controlling lactam formation
Cyclization requires the intended side-chain pair to react while other functional groups remain protected. Incorrect ring closure, incomplete cyclization, or deletion sequences can create closely related impurities with different conformations. After cleavage, chromatographic purification separates these species, and the expected mass change supports formation of the designed cyclic product. Analytical documentation should identify the salt and terminal forms as well as the base sequence.
Structure–activity questions
The constrained scaffold provides a way to study how conformation affects melanocortin-receptor recognition. Researchers can compare cyclic and linear analogs, or related terminal variants, while measuring binding and downstream signaling in receptor-defined systems. Such comparisons examine structure–activity relationships without assuming that one chemical difference determines every observed endpoint; receptor expression and assay conditions remain important experimental variables. Reference standards and system-suitability checks add confidence when comparing chromatographic batches. Because a correct nominal mass cannot distinguish every isomer or conformer, mass data should be interpreted alongside separation behavior and the known synthesis route. The objective is not merely to detect peptide material, but to support the identity of the intended cyclic form.
Product page: PT-141 research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.